Compare · ALHC vs NTRA
ALHC vs NTRA
Side-by-side comparison of Alignment Healthcare Inc. (ALHC) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALHC and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $38.87B, about 9.1x ALHC ($4.26B).
- Over the past year, ALHC is up 66.0% and NTRA is up 95.5% - NTRA leads by 29.5 points.
- NTRA has been more active in the news (27 items in the past 4 weeks vs 9 for ALHC).
- Both have 25 recent analyst ratings on file.
- Company
- Alignment Healthcare Inc.
- Natera Inc.
- Price
- $20.59+2.97%
- $271.44+0.55%
- Market cap
- $4.26B
- $38.87B
- 1M return
- -0.05%
- +23.26%
- 1Y return
- +66.02%
- +95.48%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2015
- News (4w)
- 9
- 27
- Recent ratings
- 25
- 25
Alignment Healthcare Inc.
Alignment Healthcare, Inc. provides a consumer-centric platform that delivers customized health care to seniors in the United States. It offers medicare advantage plans and health plan options to its partners and patients with customized care and service; and preferred provider organization offerings. The company was founded in 2013 and is based in Orange, California.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest ALHC
- President Maroney Dawn Christine exercised 152,068 shares at a strike of $9.06 and sold $3,687,990 worth of shares (177,068 units at $20.83) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 922,313 units (SEC Form 4)
- Chief Executive Officer Kao John E sold $5,919,361 worth of shares (298,000 units at $19.86) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Alignment Healthcare Inc.
- Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
- Chief Operations Officer Hochradel Shane J. was granted 87,719 shares (SEC Form 4)
- EVP, Corporate Affairs Konowiecki Joseph S sold $600,000 worth of shares (25,000 units at $24.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,103,816 units (SEC Form 4)
- SEC Form 144 filed by Alignment Healthcare Inc.
- EVP, Corporate Affairs Konowiecki Joseph S sold $575,000 worth of shares (25,000 units at $23.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,128,816 units (SEC Form 4)
- SEC Form 144 filed by Alignment Healthcare Inc.
- EVP, Corporate Affairs Konowiecki Joseph S sold $550,000 worth of shares (25,000 units at $22.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,153,816 units (SEC Form 4)
Latest NTRA
- Director Chapman Rowan E sold $37,101 worth of shares (135 units at $274.82) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 4,663 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $410,825 worth of shares (1,500 units at $273.88) as part of a pre-agreed trading plan (SEC Form 4)
- Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
- CO-FOUNDER Sheena Jonathan sold $836,898 worth of shares (3,150 units at $265.68) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 246,202 units (SEC Form 4)
- Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $280,000 worth of shares (1,000 units at $280.00) as part of a pre-agreed trading plan (SEC Form 4)
- SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel sold $4,574,431 worth of shares (16,800 units at $272.29) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 172,294 units (SEC Form 4)
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $818,710 worth of shares (3,000 units at $272.90) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 134,643 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update
- Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer